Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma

The outcomes of metastatic and nonresponder pediatric osteosarcoma patients are very poor and have not improved in the last 30 years. These tumors harbor a highly immunosuppressive environment, making existing immunotherapies ineffective. Here, we evaluated the use of Semliki Forest virus (SFV) vect...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrador-Cañete, Guillermo, Zalacain, Marta, Labiano, Sara, Laspidea, Virginia, Puigdelloses, Montserrat, Marrodan, Lucía, Garcia-Moure, Marc, Gonzalez-Huarriz, Marisol, Marco-Sanz, Javier, Ausejo-Mauleon, Iker, de la Nava, Daniel, Hernández-Osuna, Reyes, Martínez-García, Javier, Silva-Pilipich, Noelia, Gurucega, Elisabeth, Patiño-García, Ana, Hernández-Alcoceba, Rubén, Smerdou, Cristian, Alonso, Marta M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345771/
https://www.ncbi.nlm.nih.gov/pubmed/35949950
http://dx.doi.org/10.1016/j.omto.2022.07.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345771/
https://www.ncbi.nlm.nih.gov/pubmed/35949950
http://dx.doi.org/10.1016/j.omto.2022.07.004

Ejemplares similares